Evidence map›Paper›PMID 40860576›Full record

ArticleJCEM case reports2025

Exogenous Insulin Antibody Syndrome: A Rare Cause of Extreme Insulin Resistance Treated With High-dose Corticosteroids.

Hari Haran Rajamohan, Pierre-Nicolas Boyer, Timothy Davis, Michael Lane, Amanda Love

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hari Haran RajamohanDepartment of Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.ORCID https://orcid.org/0009-0003-8096-8678
Pierre-Nicolas BoyerDepartment of Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.ORCID https://orcid.org/0000-0002-7012-4522
Timothy DavisDepartment of Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.
Michael LaneDepartment of Immunology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.
Amanda LoveDepartment of Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exogenous insulin antibody syndrome is a rare condition characterized by extreme insulin resistance caused by antibodies that neutralize the action of insulin. An 80-year-old woman with type 1 diabetes mellitus was transferred to an Australian quaternary hospital with refractory hyperglycemia and diabetic ketoacidosis despite receiving >300 units of insulin daily. Laboratory testing revealed a very high insulin antibody titer of 6758 U/mL (6758 kU/L)(<0.4 U/mL; <0.4 kU/L). Plasmapheresis was considered but was not pursued because of hemodynamic instability, multiple comorbidities and frailty. Treatment with high-dose methylprednisolone at 1 mg/kg for 5 days and 500 mg of mycophenolate mofetil twice daily, followed by a tapering regimen of prednisone, resulted in a significant improvement in extreme insulin resistance. The total daily dose of insulin after treatment returned to a baseline of approximately 70 units and insulin antibody titers were reduced by 8-fold. Remission was maintained for more than 2 years until the patient died of an aggressive squamous cell carcinoma of the buccal mucosa.

Indexed as

corticosteroidsexogenous insulin antibody syndromeextreme insulin resistancetype 1 diabetes mellitus

Identifiers

PMID40860576
PMCPMC12371233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.